Marshall, Gerstein & Borun LLP
Aminopyrimidines as ALK inhibitors
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer. 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A A C C
A61K A61P C07D C07D
inventional inventional inventional inventional
Jianyong Shaomeng
Chen Wang